Charles Russell Speechlys advises Mander Portman Woodward on the acquisition of Justin Craig Education
Charles Russell Speechlys has advised Mander Portman Woodward Limited (MPW) on its strategic acquisition of Justin Craig Education, one of the United Kingdom’s leading exam preparation tutoring businesses, from Piper Private Equity.
A portfolio company of Los Angeles-based private equity firm Levine Leichtman Capital Partners, MPW was founded in 1973 and is based in London. It is a leading provider of high quality private education for students in their crucial transition from secondary school into UK universities. As a platform that offers courses to over 1,000 students each year at its London, Cambridge and Birmingham campuses, MPW is one of the most well-known and regarded brands in the UK education market.
The Charles Russell Speechlys’ core team comprised Private Equity partner Malcolm MacDougall and Private Equity associate Holly Sage supported by Employment associates Victoria Lamont and Kirsti Laird and Tax associate Robert Birchall.
Malcolm said “We are delighted to have worked with MPW and Levine Leichtman Capital Partners on this acquisition, which will help support MPW’s existing Easter Revision business as it continues to grow into new schools and regions. This is a great opportunity for the business and we are very pleased to have been able to assist with the process”.
Piper Private Equity was advised by Bond Dickinson LLP.
News & Insights
Government provides welcome clarity for EMI option holders who have been furloughed
The proposed amendments will provide some clarity and address concerns regarding the consequences of furloughing EMI option holders.
Charles Russell Speechlys advises Transense Technologies Plc on iTrack technology transaction with Bridgestone Corporation
Transense Technologies Plc, the provider of sensor systems for the industrial, mining and transportation markets.
Charles Russell Speechlys advises Kreos and SVB on $70m private placement for AIM listed Mereo BioPharma Group plc
Mereo BioPharma is a clinical stage UK-based biopharmaceutical company listed on the AIM market of the LSE.